• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Pharmacovigilance Analytics

Your best resource for PV analytics news, content and innovation!

  • Home
  • Pharmacovigilance Analytics
    • Sources of data
    • Methods and tools
  • Signal Detection and Management in Pharmacovigilance
  • News
  • Opinion
  • About
  • Glossary

Adverse Event (AE)

February 9, 2018 by Jose Rossello

An Adverse Event (AE) in the context of healthcare and medicine refers to any undesirable experience associated with the use of a medical product or intervention in a patient. The term is broad and encompasses any harm to a patient that occurs during medical care, regardless of whether it is caused by the medical care itself.

Here are key points about Adverse Events:

  1. Not Necessarily Caused by Treatment: An AE does not necessarily have a direct causal relationship with the treatment or medical product. For example, if a patient experiences a headache after taking a medication, that headache is an AE, but it might not be directly caused by the medication.
  2. Includes a Wide Range of Outcomes: Adverse events can include physical, mental, emotional, or functional changes that negatively impact the patient. These can range from mild symptoms like nausea or dizziness to severe outcomes like hospitalization, disability, life-threatening complications, or even death.
  3. Occurs in Various Settings: AEs can occur in any healthcare setting, including hospitals, clinics, long-term care facilities, or even at home.
  4. Includes Errors and Non-Errors: An AE might result from a medical error (like a wrong medication being given) but can also occur in the absence of errors (such as an unforeseen allergic reaction to a correctly administered drug).
  5. Reporting and Monitoring: Healthcare systems often have reporting and monitoring systems for AEs. This helps in understanding the safety profile of medical interventions, improving patient care, and informing public health decisions.
  6. Clinical Trials and Research: In the context of clinical trials, AEs are rigorously documented to assess the safety and efficacy of new treatments or medical interventions.

Understanding and managing adverse events is a crucial part of healthcare, as it directly relates to patient safety and the quality of care. Healthcare professionals are trained to recognize, report, and manage AEs to minimize harm to patients.

Related Articles:
  • Artificial Intelligence in Pharmacovigilance: Regulatory Compliance Simplified
  • Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences
  • Glossary: Case Report Form (CRF)
  • Sources of data
  • Twitter, Safety and Pharmacovigilance: All Papers Retrieved using PubMed
Related Terms:
  • Term: Adverse Event (AE)

Primary Sidebar

Subscribe in a reader

Search Website

Uses of Generative AI in Pharmacovigilance

Featured News / Posts

Signal Analytics Technology in Pharmacovigilance

Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

Pharmacovigilance plays a crucial role in ensuring public safety by monitoring, … [Read More...] about Signal Analytics Technology in Pharmacovigilance: Enhancing Drug Safety Monitoring

8 Common FDA Applications for Drugs & Biologics

The U.S. Food and Drug Administration (FDA) has several types of applications … [Read More...] about 8 Common FDA Applications for Drugs & Biologics

Key IND Enabling Studies: Navigating Preclinical Development Regulations

Investigational New Drug (IND) applications represent a critical stage in the … [Read More...] about Key IND Enabling Studies: Navigating Preclinical Development Regulations

Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Pharmacokinetics and pharmacodynamics are two fundamental pillars in the field … [Read More...] about Pharmacokinetics and Pharmacodynamics (PKPD): Fundamentals in Drug Development and Therapeutic Effectiveness

Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Regulatory authorities in the pharmaceutical industry have established standards … [Read More...] about Current Regulations Regarding Reference Safety Information (RSI): Key Aspects and Updates

Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

In the realm of patient safety and pharmacovigilance, statistical signal … [Read More...] about Methods of Statistical Signal Detection in Patient Safety and Pharmacovigilance: Key Techniques and Approaches

Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

Pharmacovigilance signal detection software plays a crucial role in … [Read More...] about Pharmacovigilance Signal Detection Software: Enhancing Drug Safety and Monitoring

What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

A Periodic Benefit-Risk Evaluation Report (PBRER) serves as a structured … [Read More...] about What is a PBRER? Understanding Periodic Benefit-Risk Evaluation Reports

Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Drug safety and pharmacovigilance are crucial aspects of public … [Read More...] about Drug Safety vs Pharmacovigilance: Exploring Conceptual Differences

Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

he Development Safety Update Report (DSUR) is a crucial document that serves as … [Read More...] about Which Sections of a DSUR Must Present Safety and Pharmacovigilance Quantitative Data: Key Components Explained

  • What is a DSUR (Development Safety Update Report)? An Essential Guide for Clinical Research
  • What is a BLA (Biologics License Application)? Essential Guide for Professionals
  • What is a PADER? – Periodic Adverse Drug Experience Report Explained

RSS ICH News

  • An error has occurred, which probably means the feed is down. Try again later.

RSS From Nature journal

  • PET-based tracking of CAR T cells and viral gene transfer using a cell surface reporter that binds to lanthanide complexes
  • Analysis and risk assessment of nitrosamines in sartans using GC-MS and Monte Carlo simulation
  • Medication safety analysis of elderly inpatients based on improved functional resonance analysis method (FRAM): a mixed methods study
  • Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data
  • Artemisinin derivatives differently affect cell death of lung cancer subtypes by regulating GPX4 in patient-derived tissue cultures

Copyright © 2025 · News Pro on Genesis Framework · WordPress · Log in